Provided by the Society of Hospital Medicine in collaboration with the American College of Emergency Physicians and Haymarket Medical Education
Supported by an educational grant from Novartis Pharmaceuticals Corporation
Each year in the United States, nearly 1 million patients present to the emergency department (ED) with heart failure (HF), usually after a delay of several days, if not weeks, from the onset of symptoms. More than 800,000 of these patients are then admitted to the hospital, although recent evidence suggests that as many as half of that population could safely be discharged from the ED after a brief observation period. The challenge for clinicians, particularly ED physicians and hospitalists, is how to identify those patients who are candidates for release to an observation unit or for discharge to home without increasing the risk of readmission or death. In part 1 of this 2-part webcast, 3 experts—an ED physician, a hospitalist, and a cardiologist—discuss optimal approaches to management of acutely worsening HF.
This activity is intended for hospitalists, emergency medicine physicians, and other clinicians who treat heart failure.
After completing the activity, the participant should be better able to:
Accurately assess risk at triage (high, low, uncertain, or mortality risk) when patients present to the emergency department with worsening symptoms of heart failure
Inform decision making on whether to hospitalize the patient, admit to the observation unit, or discharge and continue treatment from home
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
Marc A. Silver, MD, FACP, FACC, FAHA, FHFSA Chief, Division of Medical Services and Chairman, Department of Medicine (Ret.) Founder, Heart Failure Institute Advocate Christ Medical Center Clinical Professor of Medicine University of Illinois at Chicago Chicago, IL
Dr. Silver has no relevant financial relationships to disclose.
David Klimpl, MD, MS Instructor of Medicine Johns Hopkins Bayview Medical Center Department of Hospital Medicine Baltimore, MD
Dr. Klimpl has no relevant financial relationships to disclose.
Heather M. Prendergast, MD, MS, MPH, FACEP Assistant Dean of Clinical Affairs, COM Professor and Vice Chair of Academic Affairs Department of Emergency Medicine University of Illinois Medical Center Chicago, IL
Dr. Prendergast has no relevant financial relationships to disclose.
Accredited Provider Disclosures
The staff of the Society of Hospital Medicine involved in the planning and content review of this activity have no relevant financial relationships to disclose.
Educational Partner Disclosures
The American College of Emergency Physicians and Haymarket Medical Education staff involved in the planning of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Society of Hospital Medicine (SHM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Society of Hospital Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
Faculty, speakers, presenters, authors, activity medical directors, and moderators are required to disclose to the learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA-approved) as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
To receive credit for this activity, the participant must complete the pre-activity questionnaire, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.